Developer docs
API playgroundTry for free, no card

Search company profiles

aap Implantate AG

Full company profile

uuid000a3zd

Namestring
aap Implantate AG
Legal namestring
aap Implantate AG
Websiteurl
aap.de
Company typeenum
Public
Founded yearint
1990
Descriptiontext

aap Implantate AG is a publicly listed German medical device company headquartered in Berlin (Lorenzweg 5, 12099 Berlin) that develops, manufactures, and markets trauma surgery implants, principally the LOQTEQ anatomical plate system and complementary cortical screws covering more than 95% of relevant indications in upper and lower extremity trauma. Its core proprietary technology, LOQTEQ, combines fracture compression and angle-stable locking in a single surgical step with polyaxial angulation up to 15° and variable compression from 0 to 2 mm, designed to minimize cold welding between screws and plates. Two pipeline platforms extend the brand: LOQTEQ antibacterial (silver-coated implants intended to reduce surgical-site infection, with a clinical human study successfully completed in August 2025) and LOQTEQ resorbable (magnesium-hydroxylapatite implants designed to degrade after healing, eliminating second-surgery removal).

Revenue is generated through hardware sales of LOQTEQ plates, screws, and ReproBone biomaterials. In Germany the company sells directly to hospitals, hospital purchasing groups (Einkaufsgemeinschaften), and network clinics (Verbundkliniken) via a field sales force of medical product consultants; internationally it relies on a distributor network spanning approximately 25–41 countries; and in the US it operates through wholly-owned subsidiary aap Implants Inc. (Dover, DE) using a hybrid of distribution agents, selective direct sales, and partnerships with global orthopedics companies. Reported FY2025 revenue was EUR 12.5 million (+2% YoY) with an EBITDA loss of EUR -0.64 million (improved from EUR -0.85M in FY2024), while the core Trauma segment achieved a positive recurring EBITDA of EUR 0.4 million. The portfolio is protected by international patents and holds CE/MDR (Class IIb certification completed Q1 2026), FDA, NMPA, and ANVISA approvals. The company is listed on the Frankfurt Stock Exchange General Standard (XETRA: AAQ.DE), with significant insider-linked shareholders Deepblue Holding AG and Merval AG participating in multiple recent capital increases.

Short descriptiontext

aap Implantate AG is a Berlin-headquartered, Frankfurt-listed medical device company that develops and markets LOQTEQ anatomical trauma plates and screws — including pipeline antibacterial silver-coated and resorbable magnesium variants — sold to hospitals and purchasing groups directly in Germany and through distributors in 25–41 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
trauma medical devices, orthopedic implants, locking compression plates, surgical cortical screws, bone substitute materials
Industry1 code
1Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
CodeHLAHAEABPrimaryYes
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Trauma Implants
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Trauma Products - LOQTEQ® Plate System
TypeHardware Sales
Description

Revenue from anatomical plate systems and screws for trauma surgery, sold directly in Germany and through distributors internationally.

aap.de
2Trauma-Complementary Biomaterials
TypeHardware Sales
Description

Revenue from trauma-complementary biomaterials marketed through distributor network globally.

aap.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1LOQTEQ®
Description

Anatomical plate system for trauma surgery, covering over 95% of relevant indications in trauma surgery of upper and lower extremities. Includes LOQTEQ antibacterial (silver-coated implants) and LOQTEQ resorbable (magnesium-based implants) variants.

aap.de
+3 more records
Core offering1 text field

aap Implantate AG develops, manufactures, and markets trauma surgery products, with its core portfolio built around the patented LOQTEQ anatomical plate system for fractures of the upper and lower extremities (shoulder, elbow, wrist, knee, ankle), complemented by cortical screws (Lochschrauben) and the ReproBone bone substitute biomaterial. The company also develops two next-generation platform technologies: LOQTEQ antibacterial silver-coated implants to prevent implant-related infections and LOQTEQ resorbable magnesium implants that biodegrade after fracture healing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • LOQTEQ® portfolio covers >95% of relevant indications in trauma surgery of upper and lower extremities
+2 more records
Product overview1 text field

aap Implantate AG is a medical technology company specializing in trauma surgery products. The product portfolio centers on the LOQTEQ® platform system, which includes anatomical plates for various body areas (shoulder, elbow, wrist, knee, ankle) and complementary cortical screws. The LOQTEQ® technology combines fracture compression with angle-stable locking in one surgical step. The company also offers two innovative platform technologies: LOQTEQ® antibacterial (silver coating to prevent implant-related infections) and LOQTEQ® resorbable (magnesium implants with hydroxylapatite coating that dissolve after healing). Additional products include ReproBone® bone substitute. The portfolio is protected by international patents and holds regulatory approvals including CE, FDA, NMPA, and ANVISA.

Product and service5 records
1LOQTEQ Plattensystem
CategoryTrauma orthopedic implants
Description

Anatomical plate system for trauma surgery covering upper and lower extremities with angle-stable locking compression technology. The platform combines fracture compression and angle-stable locking in one surgical step, covering more than 95% of all relevant indications in trauma surgery of the shoulder, elbow, wrist, knee, and ankle. Sold to hospitals, purchasing groups, and network clinics in Germany via direct sales and internationally via distributors.

2LOQTEQ antibacterial
CategoryTrauma orthopedic implants (antibacterial)
Description

Next-generation trauma implants featuring silver coating technology that protects implants from bacterial colonization and patients from implant-related infections, one of the most critical complications of orthopedic and surgical procedures. Clinical human study successfully completed August 2025; MDR and FDA approvals in progress.

3LOQTEQ resorbable
CategoryTrauma orthopedic implants (resorbable)
Description

Resorbable magnesium implant technology with hydroxylapatite coating that enables trauma implants to be broken down in the body after fracture healing, avoiding a second surgery for implant removal. Platform technology targeting facial surgery, sports medicine, and pediatrics applications.

4Lochschrauben (Cortical Screws)
CategoryTrauma orthopedic implants (screws)
Description

Comprehensive range of cortical screws complementing the LOQTEQ plate system for trauma surgery applications of the upper and lower extremities.

5ReproBone
CategoryBone substitute biomaterial
Description

Trauma-complementary bone substitute biomaterial marketed through the distributor network globally.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Wholly-owned US subsidiary based in Dover, Delaware, responsible for US market operations. Operates hybrid distribution strategy combining distribution agents with selective direct sales and partnerships with global orthopedics companies.

2MCTeQ GmbH
Strategic tierCoreTypeOthers
Description

100% owned subsidiary based in Berlin, Germany. Part of the aap Group corporate structure.

aap.de
3MAGIC Implants GmbH
Strategic tierCoreTypeOthers
Description

100% owned subsidiary based in Berlin, Germany. Part of the aap Group corporate structure.

aap.de
4AEQUOS Endoprothetik GmbH
Strategic tierMinorTypeStrategic or Co-development Partner
Description

aap holds 4.57% participation in AEQUOS Endoprothetik GmbH, suggesting a strategic investment or partnership in the endoprosthetics field.

aap.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Chinese partner for regulatory approval of antibacterial implant technology in China. aap plans to pursue approval in China together with Youshi Medical.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Broad network of distribution partners in approximately 25-41 countries marketing trauma products and trauma-complementary biomaterials worldwide. Actively seeking new distribution partners globally.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stryker operates one of the world's largest orthopedic trauma businesses (formerly Stryker Trauma) offering plates, screws, and intramedullary nails across all major extremities. As a dominant incumbent, it competes with aap across the same trauma surgery indications and hospital purchasing channels.

TypeBroad incumbent
Description

Smith+Nephew operates a global trauma and extremities business with plating systems and sports medicine adjacencies. It is a relevant incumbent competitor for aap's trauma plates and screws portfolio in EU and international markets.

TypeBroad incumbent
Description

Arthrex is a privately-held global leader in sports medicine, orthopedics, and trauma extremity devices, including plates, screws, and soft-tissue anchors. Its extremities portfolio directly overlaps with aap's LOQTEQ wrist, elbow, and ankle indications.

TypeBroad incumbent
Description

DePuy Synthes is the largest global player in orthopedic trauma, offering comprehensive plate and screw systems across extremities. Its extensive product portfolio, surgeon training programs, and hospital contracts directly overlap with aap's LOQTEQ addressable market.

TypeBroad incumbent
Description

Zimmer Biomet is a leading global orthopedic company with a broad trauma and extremities portfolio including plates, screws, and biologics. Its global scale and trauma sales force compete head-to-head with aap in hospital tenders and surgeon adoption.

TypeDirect peer
Description

Orthofix is a global medical device company focused on spine and orthopedic trauma, with a portfolio of plates, screws, and biologics directly comparable to aap's LOQTEQ trauma platform. As a similarly-sized, publicly-listed trauma-focused company, it is the closest analog in scale and product mix.

TypeBroad incumbent
Description

Integra LifeSciences offers a portfolio of orthopedic extremity hardware, neurosurgical, and regenerative tissue products. Its extremities fixation and specialty orthopedics lines compete with aap in selected trauma and reconstructive indications globally.

TypeDirect peer
Description

Acumed is a privately-held orthopedic device company specializing in trauma and extremities implants, including plate and screw systems for upper and lower extremities. Its focused product portfolio and similar scale make it a close comparable for aap's trauma business.

TypeEmerging player
Description

Paragon 28 is a smaller publicly-traded orthopedic company focused on foot and ankle extremities, an indication area directly served by aap's LOQTEQ Sprunggelenk (ankle) plates. It represents an emerging competitor in the extremities sub-segment where aap competes.

TypeBroad incumbent
Description

B. Braun's Aesculap division is a major European-headquartered orthopedic and trauma player with plate/screw systems for extremities. As a German-headquartered peer with strong hospital penetration in EMEA, it competes with aap most directly in its home market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

aap Implantate AG

Orthopedic Trauma Implantsaap.de

aap Implantate AG is a Berlin-headquartered, Frankfurt-listed medical device company that develops and markets LOQTEQ anatomical trauma plates and screws — including pipeline antibacterial silver-coated and resorbable magnesium variants — sold to hospitals and purchasing groups directly in Germany and through distributors in 25–41 countries.

What aap Implantate AG does

aap Implantate AG is a publicly listed German medical device company headquartered in Berlin (Lorenzweg 5, 12099 Berlin) that develops, manufactures, and markets trauma surgery implants, principally the LOQTEQ anatomical plate system and complementary cortical screws covering more than 95% of relevant indications in upper and lower extremity trauma. Its core proprietary technology, LOQTEQ, combines fracture compression and angle-stable locking in a single surgical step with polyaxial angulation up to 15° and variable compression from 0 to 2 mm, designed to minimize cold welding between screws and plates. Two pipeline platforms extend the brand: LOQTEQ antibacterial (silver-coated implants intended to reduce surgical-site infection, with a clinical human study successfully completed in August 2025) and LOQTEQ resorbable (magnesium-hydroxylapatite implants designed to degrade after healing, eliminating second-surgery removal).

Revenue is generated through hardware sales of LOQTEQ plates, screws, and ReproBone biomaterials. In Germany the company sells directly to hospitals, hospital purchasing groups (Einkaufsgemeinschaften), and network clinics (Verbundkliniken) via a field sales force of medical product consultants; internationally it relies on a distributor network spanning approximately 25–41 countries; and in the US it operates through wholly-owned subsidiary aap Implants Inc. (Dover, DE) using a hybrid of distribution agents, selective direct sales, and partnerships with global orthopedics companies. Reported FY2025 revenue was EUR 12.5 million (+2% YoY) with an EBITDA loss of EUR -0.64 million (improved from EUR -0.85M in FY2024), while the core Trauma segment achieved a positive recurring EBITDA of EUR 0.4 million. The portfolio is protected by international patents and holds CE/MDR (Class IIb certification completed Q1 2026), FDA, NMPA, and ANVISA approvals. The company is listed on the Frankfurt Stock Exchange General Standard (XETRA: AAQ.DE), with significant insider-linked shareholders Deepblue Holding AG and Merval AG participating in multiple recent capital increases.

aap Implantate AG firmographics

Firmographics
Name
aap Implantate AG
Legal name
aap Implantate AG
Website
https://aap.de
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
51–100 employees
Short description
aap Implantate AG is a Berlin-headquartered, Frankfurt-listed medical device company that develops and markets LOQTEQ anatomical trauma plates and screws — including pipeline antibacterial silver-coated and resorbable magnesium variants — sold to hospitals and purchasing groups directly in Germany and through distributors in 25–41 countries.
Ownership category
akta.pro rank

aap Implantate AG industry classification

Industry
Product category
Orthopedic Trauma Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

  • Trauma medical devices
  • Orthopedic implants
  • Locking compression plates
  • Surgical cortical screws
  • Bone substitute materials

Where aap Implantate AG is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

aap Implantate AG business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Trauma Products - LOQTEQ® Plate System: Revenue from anatomical plate systems and screws for trauma surgery, sold directly in Germany and through distributors internationally.
  2. Trauma-Complementary Biomaterials: Revenue from trauma-complementary biomaterials marketed through distributor network globally.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

aap Implantate AG product offering

Product offering

Core offering

aap Implantate AG develops, manufactures, and markets trauma surgery products, with its core portfolio built around the patented LOQTEQ anatomical plate system for fractures of the upper and lower extremities (shoulder, elbow, wrist, knee, ankle), complemented by cortical screws (Lochschrauben) and the ReproBone bone substitute biomaterial. The company also develops two next-generation platform technologies: LOQTEQ antibacterial silver-coated implants to prevent implant-related infections and LOQTEQ resorbable magnesium implants that biodegrade after fracture healing.

Product overview

aap Implantate AG is a medical technology company specializing in trauma surgery products. The product portfolio centers on the LOQTEQ® platform system, which includes anatomical plates for various body areas (shoulder, elbow, wrist, knee, ankle) and complementary cortical screws. The LOQTEQ® technology combines fracture compression with angle-stable locking in one surgical step. The company also offers two innovative platform technologies: LOQTEQ® antibacterial (silver coating to prevent implant-related infections) and LOQTEQ® resorbable (magnesium implants with hydroxylapatite coating that dissolve after healing). Additional products include ReproBone® bone substitute. The portfolio is protected by international patents and holds regulatory approvals including CE, FDA, NMPA, and ANVISA.

Differentiator

Problem solved

Functional benefit

Brands

  • LOQTEQ®: Anatomical plate system for trauma surgery, covering over 95% of relevant indications in trauma surgery of upper and lower extremities. Includes LOQTEQ antibacterial (silver-coated implants) and LOQTEQ resorbable (magnesium-based implants) variants.
  • LOQTEQ® antibacterial
  • LOQTEQ® resorbable
  • ReproBone®

Products and services

  • LOQTEQ Plattensystem Anatomical plate system for trauma surgery covering upper and lower extremities with angle-stable locking compression technology. The platform combines fracture compression and angle-stable locking in one surgical step, covering more than 95% of all relevant indications in trauma surgery of the shoulder, elbow, wrist, knee, and ankle. Sold to hospitals, purchasing groups, and network clinics in Germany via direct sales and internationally via distributors.
  • LOQTEQ antibacterial Next-generation trauma implants featuring silver coating technology that protects implants from bacterial colonization and patients from implant-related infections, one of the most critical complications of orthopedic and surgical procedures. Clinical human study successfully completed August 2025; MDR and FDA approvals in progress.
  • LOQTEQ resorbable Resorbable magnesium implant technology with hydroxylapatite coating that enables trauma implants to be broken down in the body after fracture healing, avoiding a second surgery for implant removal. Platform technology targeting facial surgery, sports medicine, and pediatrics applications.
  • Lochschrauben (Cortical Screws) Comprehensive range of cortical screws complementing the LOQTEQ plate system for trauma surgery applications of the upper and lower extremities.
  • ReproBone Trauma-complementary bone substitute biomaterial marketed through the distributor network globally.

Quantifiable outcome

  • LOQTEQ® portfolio covers >95% of relevant indications in trauma surgery of upper and lower extremities
  • +2 more outcomes

Companies that use aap Implantate AG

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

aap Implantate AG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

aap Implantate AG partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • aap Implants Inc.coreChannel Partner/ Reseller/ DistributorWholly-owned US subsidiary based in Dover, Delaware, responsible for US market operations. Operates hybrid distribution strategy combining distribution agents with selective direct sales and partnerships with global orthopedics companies.
  • MCTeQ GmbHcoreOthers100% owned subsidiary based in Berlin, Germany. Part of the aap Group corporate structure.
  • MAGIC Implants GmbHcoreOthers100% owned subsidiary based in Berlin, Germany. Part of the aap Group corporate structure.
  • AEQUOS Endoprothetik GmbHminorStrategic or Co-development Partneraap holds 4.57% participation in AEQUOS Endoprothetik GmbH, suggesting a strategic investment or partnership in the endoprosthetics field.
  • Youshi MedicalminorStrategic or Co-development PartnerChinese partner for regulatory approval of antibacterial implant technology in China. aap plans to pursue approval in China together with Youshi Medical.
  • International Distributor NetworkcoreChannel Partner/ Reseller/ DistributorBroad network of distribution partners in approximately 25-41 countries marketing trauma products and trauma-complementary biomaterials worldwide. Actively seeking new distribution partners globally.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

aap Implantate AG competitors and assessment

Company assessment

Broad incumbents

  • Stryker Corporation: Stryker operates one of the world's largest orthopedic trauma businesses (formerly Stryker Trauma) offering plates, screws, and intramedullary nails across all major extremities. As a dominant incumbent, it competes with aap across the same trauma surgery indications and hospital purchasing channels.
  • Smith+Nephew: Smith+Nephew operates a global trauma and extremities business with plating systems and sports medicine adjacencies. It is a relevant incumbent competitor for aap's trauma plates and screws portfolio in EU and international markets.
  • Arthrex: Arthrex is a privately-held global leader in sports medicine, orthopedics, and trauma extremity devices, including plates, screws, and soft-tissue anchors. Its extremities portfolio directly overlaps with aap's LOQTEQ wrist, elbow, and ankle indications.
  • DePuy Synthes (Johnson & Johnson): DePuy Synthes is the largest global player in orthopedic trauma, offering comprehensive plate and screw systems across extremities. Its extensive product portfolio, surgeon training programs, and hospital contracts directly overlap with aap's LOQTEQ addressable market.
  • Zimmer Biomet: Zimmer Biomet is a leading global orthopedic company with a broad trauma and extremities portfolio including plates, screws, and biologics. Its global scale and trauma sales force compete head-to-head with aap in hospital tenders and surgeon adoption.
  • Integra LifeSciences: Integra LifeSciences offers a portfolio of orthopedic extremity hardware, neurosurgical, and regenerative tissue products. Its extremities fixation and specialty orthopedics lines compete with aap in selected trauma and reconstructive indications globally.
  • Aesculap (B. Braun): B. Braun's Aesculap division is a major European-headquartered orthopedic and trauma player with plate/screw systems for extremities. As a German-headquartered peer with strong hospital penetration in EMEA, it competes with aap most directly in its home market.

Direct peers

  • Orthofix Medical: Orthofix is a global medical device company focused on spine and orthopedic trauma, with a portfolio of plates, screws, and biologics directly comparable to aap's LOQTEQ trauma platform. As a similarly-sized, publicly-listed trauma-focused company, it is the closest analog in scale and product mix.
  • Acumed: Acumed is a privately-held orthopedic device company specializing in trauma and extremities implants, including plate and screw systems for upper and lower extremities. Its focused product portfolio and similar scale make it a close comparable for aap's trauma business.

Emerging players

  • ITS (Implant Technology Systems) / Paragon 28: Paragon 28 is a smaller publicly-traded orthopedic company focused on foot and ankle extremities, an indication area directly served by aap's LOQTEQ Sprunggelenk (ankle) plates. It represents an emerging competitor in the extremities sub-segment where aap competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

aap Implantate AG social profiles

Digital presence

aap Implantate AG compliance and trust

Trust signal

Compliance5 records

aap Implantate AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

aap Implantate AG leadership team

Management profile

Number of profiles

Profiles6 records

aap Implantate AG subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

aap Implantate AG funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

aap Implantate AG M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about aap Implantate AG

What does aap Implantate AG do?

aap Implantate AG develops, manufactures, and markets trauma surgery products, with its core portfolio built around the patented LOQTEQ anatomical plate system for fractures of the upper and lower extremities (shoulder, elbow, wrist, knee, ankle), complemented by cortical screws (Lochschrauben) and the ReproBone bone substitute biomaterial. The company also develops two next-generation platform technologies: LOQTEQ antibacterial silver-coated implants to prevent implant-related infections and LOQTEQ resorbable magnesium implants that biodegrade after fracture healing.

Is aap Implantate AG a public or private company?

aap Implantate AG is a public company. It is classified as public and is currently operating.

When was aap Implantate AG founded?

aap Implantate AG was founded in 1990. It employs 51 to 100 people.

Where is aap Implantate AG based?

aap Implantate AG is headquartered in Berlin, Germany, in the Europe region.

How does aap Implantate AG make money?

Two revenue lines are on record. Trauma Products - LOQTEQ® Plate System is the primary driver. The others are trauma-Complementary Biomaterials.

Who are aap Implantate AG's main competitors?

Broad incumbents on record are Stryker Corporation, Smith+Nephew, Arthrex, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, Integra LifeSciences and Aesculap (B. Braun). Direct peers are Orthofix Medical and Acumed. ITS (Implant Technology Systems) / Paragon 28 is listed as an emerging player.

Does aap Implantate AG have an API?

No public API is recorded for aap Implantate AG.

What industry is aap Implantate AG in?

aap Implantate AG's product category is Orthopedic Trauma Implants. Its primary akta.pro industry code is HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestAAP Implantate AG: Appointment of new board members and change of CEO at AAP Implantate AGAAP Implantate AG announced the appointment of new board members and a change in its Chief Executive Officer. The article provides no further details regarding the identity of the new executives or the strategic implications of this leadership transition. This routine corporate governance update has limited immediate market impact.InvestegateEQS-News: aap Implantate AG: Appointment of new board members and change of CEO at aap Implantate AGaap Implantate AG has appointed Cornelius Fink as COO and Nicole Kassel as CFO to its Management Board, initiating a succession plan that sees current CEO Rubino Di Girolamo step down on December 31, 2026. The supervisory board cited the company's recent full MDR certification and stable foundation as key factors enabling this leadership transition to support future growth. Di Girolamo will remain with the company as an advisor focusing on antibacterial surface technology during and after the transition.FinanzNachrichten.deaap Implantate: Zweites Halbjahr soll bessere Dynamik bringenaap Implantate reported a decline in first-half 2026 revenue to 6.0 million euros, up from 6.2 million euros in the prior year period. However, the company improved its EBITDA loss to 0.1 million euros, down from 0.3 million euros, while maintaining an EBIT loss of 1.0 million euros. Management indicated that better dynamics are expected for the second half of the year.FinanzNachrichten.deEQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHGEQS Group announced the upcoming publication of financial reports for aap Implantate AG, including a semi-annual report scheduled for August 18, 2026. The announcement was made via EQS News, providing details about the report and the company.Aapaap Implantate AGaap Implantate AG announced the successful placement of a 5.7% capital increase from authorized capital at EUR 1.34 per share, generating EUR 1.06 million to fund investment in antibacterial implant technology approval processes. The company reported strong financial results, including a 15% sales increase in Q3 2025 and a notable boost in regional markets, alongside progress in clinical trials for antibacterial surface technology. The company also obtained medical device regulation (MDR) certification and completed a significant clinical trial for its antibacterial implants, boosting its market development prospects.GlobeNewswireIntegra LifeSciences Announces Agreement with aap to Distribute LOQTEQ® Distal Radius SystemIntegra LifeSciences signed an agreement with aap Implantate AG to distribute the LOQTEQ Distal Radius System in the United States. The system offers multiple plate options for fracture patterns and intra-operative efficiency. The alliance aims to expand aap's US footprint in upper extremity trauma.GlobeNewswireaap concludes distribution contract with leading US healthcare service provideraap Implantate AG concluded a distribution contract with a leading US healthcare service provider for its LOQTEQ products, starting with a 12-month pilot in selected states. If successful, distribution will expand to further states, supporting planned sales growth in North America.GlobeNewswireDGAP-Adhoc: aap Implantate AG: Annual financial statements 2015: Sales at EUR 28 million within the guidance and EBITDA KEUR 400 below the forecastaap Implantate AG reported 2015 sales of EUR 28 million, within guidance, but EBITDA of EUR -1.9 million fell KEUR 400 below the forecast. The shortfall stems from a one-time inventory value adjustment of KEUR 700 due to portfolio streamlining. The company also signed a sale agreement for its subsidiary aap Biomaterials GmbH.GlobeNewswireDGAP-PVR: aap Implantate AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionOn 29 October 2015, Fidelity Funds SICAV, FIL Investments International, FIL Holdings (UK) Limited, and FIL Limited each reported that their voting rights in aap Implantate AG fell below the 3% threshold, amounting to 1.47% (453,215 shares). The announcement was disseminated by DGAP-PVR for Europe-wide distribution.GlobeNewswireDGAP-PVR: aap Implantate AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionStichting Bewaarder Ratio Capital Partners and Ratio Capital Management B.V. each exceeded the 10% voting rights threshold on aap Implantate AG on 29 October 2015, holding 13.30% (4,100,000 votes). The announcement was disseminated by DGAP under the German Securities Trading Act.